Biogen
BIIB
1,098 hedge funds and large institutions have $45.8B invested in Biogen in 2020 Q1 according to their latest regulatory filings, with 113 funds opening new positions, 325 increasing their positions, 476 reducing their positions, and 102 closing their positions.
58% more funds holding in top 10
Funds holding in top 10: 31 → 49 (+18)
11% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 102
2% more capital invested
Capital invested by funds: $45B → $45.8B (+$782M)
0% less funds holding
Funds holding: 1,103 → 1,098 (-5)
0.86% less ownership
Funds ownership: 84.19% → 83.33% (-0.86%)
18% less call options, than puts
Call options by funds: $1.24B | Put options by funds: $1.51B
32% less repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 476
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$690M |
| 2 |
Primecap Management
Pasadena,
California
|
+$236M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$221M |
| 4 |
O
OrbiMed
New York
|
+$126M |
| 5 |
BlackRock
New York
|
+$117M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$354M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$337M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$322M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$296M |
| 5 |
ClearBridge Investments
New York
|
-$222M |
BIIB Hedge Fund Activity: Q1 2020 in Review
1,098 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2020, worth a combined $45.8B — up 1.7% from $45B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new BIIB positions and 102 closed out — a net gain of 11 holders — while 325 added to existing stakes and 476 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $690M. The largest seller was D.E. Shaw & Co, cutting an estimated $354M.
- 1,098 institutional investors held Biogen (BIIB) as of Q1 2020, down from 1,103 in Q4 2019.
- Funds reported $45.8B of Biogen stock for Q1 2020, up 1.7% quarter-over-quarter.
- 113 funds opened new Biogen positions in Q1 2020 and 102 closed out, a net change of +11 holders.
- The largest Biogen buyer in Q1 2020 was T. Rowe Price Associates, an estimated $690M added.
- The largest Biogen seller in Q1 2020 was D.E. Shaw & Co, an estimated $354M sold.
Based on aggregated 13F filings for Q1 2020.